Amankwah, E. K.Kelemen, L. E.Wang, Q.Song, H.Chenevix-Trench, G.Beesley, J.Webb, P. M.Pearce, C. L.Wu, A. H.Pike, M. C.Stram, D. O.Chang-Claude, J.Wang-Gohrke, S.Ness, R. B.Goode, E. L.Cunningham, J. M.Fridley, B. L.Vierkant, R. A.Tworoger, ShelleyWhittemore, A. S.McGuire, V.Sieh, W.Gayther, S. A.Gentry-Maharaj, A.Menon, U.Ramus, S. J.Rossing, M. A.Doherty, J. A.Goodman, M. T.Carney, M. E.Lurie, G.Wilkens, L. R.Kruger Kjaer, S.Hogdall, E.Cramer, DanielTerry, KathrynGarcia-Closas, M.Yang, H.Lissowska, J.Anton-Culver, H.Ziogas, A.Schildkraut, J. M.Berchuck, A.Pharoah, P. D. P.2016-06-172011Amankwah, E. K., L. E. Kelemen, Q. Wang, H. Song, G. Chenevix-Trench, J. Beesley, P. M. Webb, et al. 2011. “Prostate Cancer Susceptibility Polymorphism Rs2660753 Is Not Associated with Invasive Ovarian Cancer.” Cancer Epidemiology Biomarkers & Prevention 20 (5) (March 17): 1028–1031. doi:10.1158/1055-9965.epi-11-0053.1055-9965http://nrs.harvard.edu/urn-3:HUL.InstRepos:27336533Background We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC) [odds ratio (OR)=1.2, 95% confidence interval (CI)=1.0-1.4, Ptrend=0.01] that showed a stronger association with the serous histological subtype (OR=1.3, 95% CI=1.1-1.5, Ptrend=0.003). Methods We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR=1.0, 95% CI=0.9-1.1, Ptrend=0.61; serous: OR=1.0, 95% CI=0.9-1.1, Ptrend=0.85) or from the combined analysis of discovery and replication studies (all: OR=1.0, 95% CI=1.0-1.1, Ptrend= 0.28; serous: OR=1.1, 95% CI=1.0-1.2, Ptrend=0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions Although rs2660753 is a strong a prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.en-USchromosome 3pSNPovarian cancerrisk factorsJournal Article2016-06-1710.1158/1055-9965.EPI-11-0053